@Jadewade absolutely.
It’s a great result, for me.
This is how a painting looks when it’s pulled out of the gutter.
Turnarounds require creativity, patience, and immense risk taking ability.
Posts tagged Value Pickr
Indiabulls Housing – A compounder from here? (29-05-2024)
i dont this divestment is needed, they are already operating at 1.5-2x levels of gearing and hence ROEs are suppressed, they are well capitalized with a CAR of 30% and above, if in case they are raising further equity, it only means , they need more CAR to wipe off bad loans.
so wahatever book value is there – it will be depleated due to provisioning, however, if they keep providing only rationally every quarter and keep diverting all the recovery amount to provisioning, there is till hope that it can attain book value multiples as mentioned by many boarders in above posts.
my best guess is – of the 19-20kcr book value – market is already factoring a default of 10-12kcr. of loan book. (As of March 22 – loan book was around 60k cr) – right now the AUM is 65k – waiting for breakup details in filings and concall transcript.
Screener.in: The destination for Intelligent Screening & Reporting in India (29-05-2024)
Hi,
how can I add an column for 5 year median EV/EBITDA and 5 year median market cap to sale?
Basically I want the data that is available in the graph in the column.
Indiabulls Housing – A compounder from here? (29-05-2024)
Also Santosh- the legacy book as they define is – loan book as of Dec 2022 or FY22 – need to check the concall as i was listening while sleeping. any thing prior to that is called as legacy loan book – they plan to reduce that to 5000cr by FY27.
The 10000 which you mentioned is not in balance sheet – its already written off, but trust me, whatever is being recovered – is being further utilized towards creating provisions on legacy book.
Like they did for AIF provision reversal this quarter.
Hope this helps
Narayana Hrudayalaya Ltd (29-05-2024)
The results seem nice and the margins are good too, but the capex guidance for 2025 is too much. Company guided for same kind of capex for FY24 also but it seems the plan has not worked out as expected. Now, for FY25 also, the company has set huge capex targets. Can anyone tell their views on this?
Disc. Invested. Baised
Wockhardt – A story with twist and turn (29-05-2024)
Drug Discovery Update:
WCK 5222 (ZAYNICH): We continue to recruit more patients for our global clinical trial and
have recruited 392 patients. Recruitment of more than 100 patients has been done during the
current quarter. Clinical Trial study progressing in 9 countries. We have completed 30 patients
for compassionate use after approval of usage by DCGI. The product resulted in 100% cure
and was found to be safe even when administered upto 60 days.
Meropenem Resistance Clinical Trial: DCGI has advised to do a Clinical Trial of 60 patients
study. Patient recruitment process has been initiated. This Clinical Trial would be completed
within the next 8 to 9 months post which WCK 5222 (ZAYNICH) can be launched in India by
early 2025.
WCK 4873 (MIQNAF): The Company is pleased to announce the completion of the pivotal
Phase 3 pneumonia study of its antibiotic Nafithromycin WCK 4873 (MIQNAF). The product
has been filed for DCGI approval which is expected in the Q3FY25. Commercial launch
expected in Q4FY25.
After 30 years, a new oral antibiotic MIQNAF (WCK 4873) will be shortly introduced in India
and it is for Community Acquired Pneumonia with a success rate of over 97%. This will meet
a major antibiotic community need as existing drugs like Azithromycin has high resistance of
60%. It is only a three-day treatment and it has eight times higher lung concentration than
Azithromycin
https://www.bseindia.com/xml-data/corpfiling/AttachLive/f975f9fc-b6fd-4fd7-972e-c8a1ca66ad3e.pdf
PDS Limited – A platform for entrepreneurs (29-05-2024)
I would say PDS is operating in a cyclical industry that’s going through a downcycle. Demand is yet to be revived. Poor cycle brings with it a lot of opportunities as well. The company has been able to increase its stake in many manufacturing companies( esp in Sri Lanka. They have also been able to sign many sourcing agreements with major brands. I would say PDS is in a growth phase now and with the cycle turning so will its fortunes.
Discl: Invested. Have purchases in last 30 days
Bull therapy 101-thread for technical analysis with the fundamentals (29-05-2024)
AVG
Last leg has begun ,it seems .
DHP India Ltd – Regulators and Fittings (29-05-2024)
DHP performance in FY 2024 has been highly disappointing.
1. EBIT margin fell from 28% in FY 2023 to 7% in FY2024
2. Sales dropped by ~51% (from Rs 109Cr to Rs 53Cr this year)
3. What intrigued me the most is that despite the drop in sales and EBIT margin, the net profit and
EPS increased by ~12.7%. Upon digging further I observed two things:
a) Other income increased from Rs 1.6Cr in FY2023 to Rs 26.9Cr in FY2024. This means almost all of the net profit of Rs 26.4Cr is driven by this increase in other income.
b) The tax rate in dropped ~25.8% in FY2023 to ~13.5% in FY2024.
There are two primary conclusions from these observations:
- The quality of earnings deteriorated considerably. Has the management played around with the numbers of other income and tax% to boost earnings? I am compelled to believe that this is indeed the case.
- The firm does not have a moat. At least not as strong or as wide as one would like to think. I think that the business fundamentals have deteriorated considerably. The drastic drop in EBIT and EBITDA margins indicates this. The last time the firm faced strong headwinds was in 2020. But even then it was able to maintain EBIT margin at ~21.3%
Counterviews invited.